Life Sciences Tools and Services

Hotgen

Hotgen released FY2026 Q1 earnings on April 24 Pre-Market (BJT), actual revenue CNY 116.03 M, actual EPS CNY -0.77

Hotgen to Release FY2025 Earnings on April 25 During-Market (BJT), Forecast Revenue CNY 655 M, EPS CNY 0.6

Hotgen to Release FY2026 Q1 Earnings Report on April 25, Pre-Market BJT

Hotgen released FY2025 Q4 earnings on February 26 During-Market (BJT), actual revenue CNY 95.17 M, actual EPS CNY -1.0663

Hotgen released FY2025 annual earnings on February 26 During-Market (BJT), actual revenue CNY 407.69 M (forecast CNY 655 M), actual EPS CNY -2.24 (forecast CNY 0.6)

Hotgen released FY2025 9 Months Earnings on October 23 After-Market BJT, actual revenue CNY 309.71 M, actual EPS CNY -1.2326

Hotgen released FY2025 Q3 earnings on October 23 After-Market (BJT), actual revenue CNY 105.8 M, actual EPS CNY -0.2932

Hotgen to Release FY2025 Q3 Earnings on October 24 After-Market (BJT)

Hotgen released FY2025 Semi-Annual earnings on August 29 After-Market (BJT), actual revenue CNY 203.91 M, actual EPS CNY -1.1112

Hotgen released FY2025 Q2 earnings on August 29 After-Market (BJT), actual revenue CNY 110.67 M, actual EPS CNY -0.6793

Hotgen FY2025 Semi-Annual Earning Release on August 30, 2025 (BJT)

Zhou Zin of Huo Jing Bio Reduces Holding by Nearly One Million Shares

Biotree Develops Chikungunya Virus Antibody Test Kit

Zhou Xin of Huo Jing Bio 减持股份

Sinognos Biotech's Affiliate Completes Phase Ib Clinical Enrollment for SGC001 Injection

Kaiyuan Securities Initiates Coverage with Buy Rating on Huo Jing Bio

Huojing Biotech's ESG Rating Dropped to CCC

JuShi Biotech Issues a Price Movement Announcement

Jaykell Obtains Multiple Certifications and Patents

Shareholder Zhouxin of HuoShi Biotech plans to reduce holdings by 1.9416%

688068

Hotgen announced that as of March 31, 2026, the company has repurchased a total of 904,054 shares through its dedicated securities account for share repurchase, accounting for 0.98% of the total share capital. The highest transaction price for the repurchase was RMB 176.79 per share, and the lowest price was RMB 145.59 per share, with a total payment of RMB 150 million. This repurchase complies with relevant laws and regulations and the company's plan

36Kr

Hotgen: Has repurchased 904,100 shares, using a total of 150 million yuan

603598

688767

36Kr learned that the three major indices of A-shares collectively closed higher, with the Shanghai Composite Index rising 1.38% to return to 4,000 points, the Shenzhen Component Index rising 2.24%, and the ChiNext Index rising 2.85%; the semiconductor, cultural media, and biotechnology sectors led the gains, with Dongwei Semiconductor, Inly, and BIOTEST BIOTECH hitting the daily limit, and Hotgen rising over 8%; the energy, catering and tourism, and paper-making sectors saw the largest declines, with China National Offshore Oil Corporation falling over 3%, Guilin Tourism dropping over 2%, and Sun Paper falling over 1%

Inly

BIOTEST BIOTECH

The three major A-share indices collectively closed higher, with the Shanghai Composite Index returning to 4,000 points

Hotgen's affiliated company Hangzhou Aorui Biotechnology Co., Ltd. has obtained the domestic Class III medical device registration certificate. The product is a gene methylation detection kit, suitable for the in vitro qualitative detection of methylation of multiple genes in human plasma, primarily used for assisting in the diagnosis of suspected primary liver cancer

Zhitong

Hotgen's invested company has obtained domestic Class III medical device registration certificate

According to the Zhitong Finance APP, Hotgen disclosed its third-quarter report for 2025. The company achieved revenue of 310 million yuan in the first three quarters, a year-on-year decrease of 19.8%; the net loss attributable to shareholders of the listed company was 109 million yuan; the net profit excluding non-recurring items was a loss of 148 million yuan; basic earnings per share were -1.23 yuan

Hotgen released its performance for the first three quarters, with a net loss attributable to the parent company of 109 million yuan

Hotgen announced that its affiliated company ShunJing Pharmaceutical's innovative drug SGC001 has achieved positive preliminary results in Phase Ib clinical research. The study shows that in patients with anterior ST-segment elevation myocardial infarction receiving PCI treatment, SGC001 demonstrated an effective trend in myocardial protection in the 600mg and 900mg dosage groups compared to the placebo group, with a significant reduction in the percentage of myocardial infarction area (IS%) and a shorter time for high-sensitivity cardiac troponin I and high-sensitivity C-reactive protein to return to normal. The project will continue to advance according to the clinical trial protocol

Hotgen's invested company SGC001's innovative drug Phase Ib clinical trial has obtained positive preliminary results

603222

300204

688202

300436

688166

The concept of innovative drugs has rebounded, with Chimin gaining 6 limit-ups in 12 days, Staidson BioPharm rising over 7%, Hotgen increasing over 5%, and stocks like Medicilon, Cosunter, and BrightGene also seeing gains

Chimin

Staidson BioPharm

Medicilon

Cosunter

BrightGene

According to the Zhitong Finance APP, Hotgen announced that the company and its subsidiaries recently obtained 5 domestic medical device registration certificates, 1 cosmetics filing, 1 authorized patent, and 1 computer software copyright. The acquisition of these qualifications enriches the variety of the company's products, further improves the business areas related to in vitro diagnostics and consumer goods, enhances the company's intellectual property protection system, facilitates further improvement of the company's market expansion capabilities, and enhances the company's core competitiveness

Hotgen and its subsidiaries have recently obtained multiple qualifications

Hotgen announced that the innovative drug SGC001 injection of its affiliated company Beijing ShunJing Biomedical Technology Co., Ltd. has made smooth progress in Phase I clinical research. The project has completed the Phase Ia study with healthy volunteers, and the Phase Ib study with patients suffering from anterior ST-segment elevation myocardial infarction is also proceeding smoothly. Clinical observations of all subjects have been completed, and the data has been locked and unblinded. SGC001 has shown good safety and tolerability in both groups, with no serious adverse events reported, and the preliminary efficacy results are generally in line with expectations. Statistical analysis is currently underway

Hotgen: The Phase I clinical research progress of the innovative drug SGC001, in which the company holds shares, is proceeding smoothly

Hotgen(688068.SH)